Literature DB >> 17762567

Management of peripheral T-cell non-Hodgkin's lymphoma.

Steven M Horwitz1.   

Abstract

PURPOSE OF REVIEW: Peripheral T-cell lymphomas are an uncommon and heterogeneous group of non-Hodgkin's lymphomas that are noted for their particularly poor prognosis. Their rarity has resulted in few data being available to allow formulation of optimal treatment approaches. There remains no widely accepted standard therapy. A new and increasing interest in studying these lymphomas is leading to advances in our understanding, which is widening options for management. RECENT
FINDINGS: Historically, peripheral T-cell lymphomas were treated with strategies borrowed from management of aggressive B-cell lymphomas. Investigators have recognized the inadequacy of these approaches, and we are beginning to receive results, often preliminary, of studies specifically designed to evaluate T-cell lymphomas. These range from transplantation approaches, to better prognostic schemes and to attempts at molecular characterization, and new drugs are being developed specifically for their activity against T-cell lymphomas.
SUMMARY: Research in T-cell lymphomas is still mainly preliminary and studies tend to be small. Nonetheless, our understanding of these disorders is increasing, and data on new and hopefully better approaches are emerging.

Entities:  

Mesh:

Year:  2007        PMID: 17762567     DOI: 10.1097/CCO.0b013e3282ce6f8f

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  12 in total

Review 1.  Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.

Authors:  Swaminathan P Iyer; Francine F Foss
Journal:  Oncologist       Date:  2015-06-22

2.  Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.

Authors:  Owen A O'Connor; Barbara Pro; Lauren Pinter-Brown; Nancy Bartlett; Leslie Popplewell; Bertrand Coiffier; Mary Jo Lechowicz; Kerry J Savage; Andrei R Shustov; Christian Gisselbrecht; Eric Jacobsen; Pier Luigi Zinzani; Richard Furman; Andre Goy; Corinne Haioun; Michael Crump; Jasmine M Zain; Eric Hsi; Adam Boyd; Steven Horwitz
Journal:  J Clin Oncol       Date:  2011-01-18       Impact factor: 44.544

3.  Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma.

Authors:  S Horwitz; B Coiffier; F Foss; H M Prince; L Sokol; M Greenwood; D Caballero; F Morschhauser; L Pinter-Brown; S P Iyer; A Shustov; J Nichols; J Balser; B Balser; B Pro
Journal:  Ann Oncol       Date:  2015-01-20       Impact factor: 32.976

4.  Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.

Authors:  Bertrand Coiffier; Barbara Pro; H Miles Prince; Francine Foss; Lubomir Sokol; Matthew Greenwood; Dolores Caballero; Franck Morschhauser; Martin Wilhelm; Lauren Pinter-Brown; Swaminathan Padmanabhan Iyer; Andrei Shustov; Tina Nielsen; Jean Nichols; Julie Wolfson; Barbara Balser; Steven Horwitz
Journal:  J Hematol Oncol       Date:  2014-01-23       Impact factor: 17.388

5.  Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma.

Authors:  Francine Foss; Bertrand Coiffier; Steven Horwitz; Barbara Pro; H Miles Prince; Lubomir Sokol; Matthew Greenwood; Adam Lerner; Dolores Caballero; Eugeniusz Baran; Ellen Kim; Jean Nichols; Barbara Balser; Julie Wolfson; Sean Whittaker
Journal:  Biomark Res       Date:  2014-09-08

6.  Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial.

Authors:  Francine Foss; Steven Horwitz; Barbara Pro; H Miles Prince; Lubomir Sokol; Barbara Balser; Julie Wolfson; Bertrand Coiffier
Journal:  J Hematol Oncol       Date:  2016-03-10       Impact factor: 17.388

7.  Long-Term Treatment with Romidepsin in Patients with Peripheral T-Cell Lymphoma.

Authors:  Claudius Irlé; Jonathan Weintraub
Journal:  Case Rep Hematol       Date:  2016-08-25

8.  Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma.

Authors:  Francine Foss; Barbara Pro; H Miles Prince; Lubomir Sokol; Dolores Caballero; Steven Horwitz; Bertrand Coiffier
Journal:  Cancer Med       Date:  2016-12-16       Impact factor: 4.452

Review 9.  Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.

Authors:  Lisa Barbarotta; Kristen Hurley
Journal:  J Adv Pract Oncol       Date:  2015 Jan-Feb

Review 10.  Use of class I histone deacetylase inhibitor romidepsin in combination regimens.

Authors:  Adam Petrich; Chadi Nabhan
Journal:  Leuk Lymphoma       Date:  2016-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.